Juvenile Diabetes Research Foundation

Juvenile Diabetes Research Foundation

The JDRF Utah chapter is taking an active stance in the fight against diabetes and sharing its latest research tonight.
The JDRF (Juvenile Diabetes Research Foundation) Utah chapter is taking an active stance in the fight against diabetes and sharing its latest research Thursday, March 14, 2013 at the Little American Hotel from 6 - 8 p.m. Christopher B. Newgard, PhD, director of the Sarah W. Stedman Nutrition and Metabolism Center and the W. David and recipient of several diabetes coveted research awards from the JDRF, American Diabetes Association, National Institute of Health, and Bristol-Meyers Squibb, is making a special trip to Utah to share the most hopeful research on the disease.

In Utah, diabetes claims 128,000 people with the disease and 660,000 with pre-diabetes. In the United States, nearly 26 million children and adults that have diabetes, and another 79 million with pre-diabetes. The cost to treat this disease in America is $174 billion, $1 out of every $5 in healthcare costs.

"We are thrilled to have such a distinguished researcher share his intricate knowledge of diabetes research with us," said Laura Western, executive director of JDRF, Utah. "We need to know not only how close we are to finding a cure for this devastating disease but also the latest therapies in treating diabetes so the millions of people fighting can stay healthy."

What is a Research Update?
This event offers an exclusive opportunity to hear about the progress of diabetes research and treatments from experts in science and research. The dinner will cover areas of prominent interest such as:

Immune Therapies: These therapies stop the immune attack on insulin-producing beta cells and prevent an immune attack on regenerated beta cells or other insulin-producing cells used to replace beta cells.
Beta Cell Therapies: These therapies restore the body's ability to make insulin through regeneration of insulin-producing beta cells and replacement of the beta cells lost to diabetes.
Glucose Control: These therapies focus on dramatically improving blood glucose control while avoiding dangerous highs and lows in people at all stages of type 1 diabetes.
Complication Therapies: These therapies focus on freeing people from the devastating long-term complications of type 1 diabetes, including diseases of the eyes, nerves, kidneys and heart.

Christopher B Newgard, PhD
Christopher Newgard, PhD is the director of the Sarah W. Stedman Nutrition and Metabolism Center and the W. David and Sarah W. Stedman Distinguished Professor of Pharmacology and Cancer Biology at Duke University Medical Center. Dr. Newgard's research focuses on application of an interdisciplinary approach for understanding diabetes and obesity mechanisms involving gene discovery, metabolic engineering and comprehensive tools of metabolic analysis. Dr. Newgard has authored more than 250 peer-reviewed and review articles, and has been the recipient of several awards, including the Kayla Grodsy Award for Outstanding Basic Science Research from the JDRF (1999), the Outstanding Scientific Achievement (Lilly) Award from the ADA (2001), the Solomon Berson Prize of the American Physiological Society (2003) and a Freedom to Discover Award in Metabolic Research from Bristol-Meyers Squibb (2006).

About JDRF
JDRF is the worldwide leader for research to cure type 1 diabetes. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide.

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.5 billion to diabetes research, including $107 million last year. More than 80 percent of JDRF's expenditures directly support research and research-related education. For more information, please visit http://www.jdrf.org.

###Press Release from JDRF

Page: [[$index + 1]]
comments powered by Disqus